Join Arrowhead Pharmaceuticals for a virtual analyst and investor event featuring Professor Gerald Watts (University of Western Australia, Perth), who will join company management to discuss new Phase 3 clinical data from the PALISADE study of plozasiran (ARO-APOC3) in adults with familial chylomicronemia syndrome (FCS). The results will be presented at the European Society of Cardiology (ESC) Congress 2024, being held in London August 30 through September 2, 2024.

A live question and answer session will follow the formal presentation.